FDA warns about unapproved medications from a Canadian supplier

.

FDA warns about unapproved medications from a Canadian supplier

The U. S. Food & Drug Administration (FDA) has warned more than 350 medical practices that they might have received unapproved, counterfeit or unsafe medications from a Canadian supplier.

The federal food and drugs regulator said that the medications, including unapproved variants of Botox, could harm patients as they could be counterfeit or contaminated.

The foreign supplier who allegedly supplied the unapproved medications to the U. S. medical practices is operated by Canada Drugs, which is also called Quality Specialty Products (QSP), QP Medical or Bridgewater Medical.

In the letter written to the medical practices, the federal agency said, "FDA is very concerned that products distributed by these suppliers may cause harm to patients, because they may be unsafe or ineffective."

The FDA also warned doctors about purchasing drugs from any source other than pharmacies licensed by the U. S. authorities.

Dr. Peter B. Fodor, a plastic surgeon and an expert on Botox, also warned that using a non-FDA approved Botox could be very dangerous.

This is the fifth warning issued by the FDA this year about a foreign supplier supplying unapproved medications.

 


Latest News

Ford Shares Drop With Profit Concerns
Dominion LNG Export Project Gets Green Signal from FERC
Second Quarter Shows Fastest Growth of U.S Economy
Stronger Safeguarding Rules for Service Members Against Predatory Lenders
Yahoo Urged to Buy Rival AOL Inc.
Slowing Down of Inflation May Make it Difficult for BOJ to Achieve its Target
B.K. Modi’s CIO Plans to Start Pre-IPO Fund
American Soda makers Promise to Trim Twenty Percent Calories by 2025
Federal Reserve Bank of Dallas has Hired a Search Firm to Find Suitable Replacem
Stricter Rules on Tax Inversion Push Down Stocks of Firms Considering Such Moves
Brazilian President Says Growth in the U.S. Could Result in an Improvement of Br
Anonymous Whistleblower to get $30 Million from SEC